key: cord-0754203-lpp1m3sk
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Comment on: Thrombocytopenia in a teen with sickle cell disease following COVID‐19 vaccination
date: 2021-08-19
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.29303
sha: a8ce3204e0ec57ea6ec63652f37b65805a1d8585
doc_id: 754203
cord_uid: lpp1m3sk

nan

The American Society of Pediatric Hematology/Oncology

To the Editor:

We would like to share ideas on the publication "Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination." 1 The adverse event of new COVID-19 vaccine is an interesting issue. For a case with underlying disease, there might be a possible risk. Thrombocytopenia is a commonly reported adverse event after COVID-19 vaccination and might be associated with automimmunity. 2 For a person with sickle cell disease, the problem of a thrombohemostatic disorder following vaccination is possible. Not only immunopathological process but also change of blood viscosity might be induced. In general, after COVID-19 vaccination, there will be increased blood viscosity that can further result in a thrombohemostatic disorder. 3 In sickle cell anemia, there is background high blood viscosity 4 ; hence, there might be an increasing chancefor a high blood viscosity problem inducing clot and relative thrombocytopenia.

The authors declare that there is no conflict of interest. 

Thrombocytopenia in a teen with sickle cell disease following COVID-19 vaccination. Pediatr Blood Cancer. 2021:e29271

Thrombocytopenia after COVID-19 vaccination

Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19

Whole blood viscosity and red blood cell adhesion: potential biomarkers for targeted and curative therapies in sickle cell disease